Europe Biopharmaceutical Cmo And Cro Market Size & Outlook
Europe biopharmaceutical cmo and cro market, 2017-2030 (US$M)
Related Markets
Europe biopharmaceutical cmo and cro market highlights
- The Europe biopharmaceutical cmo and cro market generated a revenue of USD 9,073.9 million in 2021.
- The market is expected to grow at a CAGR of 6.7% from 2022 to 2030.
- In terms of segment, mammalian was the largest revenue generating source in 2021.
- Mammalian is the most lucrative source segment registering the fastest growth during the forecast period.
- Country-wise, France is expected to register the highest CAGR from 2022 to 2030.
Europe data book summary
| Market revenue in 2021 | USD 9,073.9 million |
| Market revenue in 2030 | USD 16,258.9 million |
| Growth rate | 6.7% (CAGR from 2021 to 2030) |
| Largest segment | Mammalian |
| Fastest growing segment | Mammalian |
| Historical data covered | 2017 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Mammalian, Non-mammalian |
| Key market players worldwide | Boehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung BioLogics, Thermo Fisher Scientific Inc, R1 RCM Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Binex, Charles River Laboratories International Inc, Icon PLC, PAREXEL, Labcorp Holdings Inc |
Other key industry trends
- In terms of revenue, Europe region accounted for 30.9% of the global biopharmaceutical cmo and cro market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Latin America is the fastest growing regional market and is projected to reach USD 1,536.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biopharmaceutical CMO And CRO Market Scope
Biopharmaceutical CMO And CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe biopharmaceutical cmo and cro market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical cmo and cro market will help companies and investors design strategic landscapes.
Mammalian was the largest segment with a revenue share of 63.63% in 2021. Horizon Databook has segmented the Europe biopharmaceutical cmo and cro market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2017 to 2030.
Presence of established market players coupled with superior contract research and manufacturing capabilities is anticipated to drive the market growth in Europe. Furthermore, increasing investments by multinational companies are anticipated to boost the market growth.
Regulatory framework for the development of biopharmaceutical products in the EU is expected to undergo major changes, which may affect market access or entry. The market is expected to grow lucratively in this region due to stringent regulatory policies.
Reasons to subscribe to Europe biopharmaceutical cmo and cro market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe biopharmaceutical cmo and cro market databook
-
Our clientele includes a mix of biopharmaceutical cmo and cro market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe biopharmaceutical cmo and cro market , including forecasts for subscribers. This continent databook contains high-level insights into Europe biopharmaceutical cmo and cro market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe biopharmaceutical cmo and cro market size, by country, 2017-2030 (US$M)
Europe Biopharmaceutical CMO And CRO Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
